Document:

<PAGE>
                                                                   EXHIBIT 10.10

Extended COLLABORATION AGREEMENT

by and between

STEREOTAXIS, INC. A CORPORATION DULY ORGANIZED AND EXISTING UNDER THE LAWS OF
DELAWARE AND HAVING ITS HEADQUARTERS AT ST. LOUIS, USA

(hereinafter referred as "Stereotaxis")

and

SIEMENS AKTIENGESELLSCHAFT, MEDICAL SOLUTIONS, A CORPORATION DULY ORGANIZED AND
EXISTING UNDER THE LAWS OF GERMANY AND HAVING OFFICES AT FORCHHEIM, GERMANY

(hereinafter referred to as "Siemens")

on

the integration of the Stereotaxis magnetic guiding component (NIOBE) with
Siemens Imaging Technology
<PAGE>
                                       2

PREAMBLE

Pursuant the COLLABORATION AGREEMENT of June 8, 2001 ("COLLABORATION
AGREEMENT"), Siemens and Stereotaxis have integrated the NIOBE SYSTEM and the
ARTIS dFC FLUOROSCOPY SYSTEM to provide an integrated interventional suite
("INTEGRATED CATH LAB") in the field of cardiology, providing unique clinical
capabilities by integration of digital instrument control and X-ray imaging via
the COMMON USER INTERFACE (defined below). Under the COLLABORATION AGREEMENT,
Siemens and Stereotaxis have also coordinated their marketing, promotions and
sales activities in respect of the INTEGRATED CATH LAB to facilitate placements
at leading interventional institutions.

Siemens and Stereotaxis' mutual goal is to extend their collaboration:

         (i)      To co-develop and commercialize an advanced cardiology cath
                  lab ("ADVANCED CARDIOLOGY CATH LAB") providing unique three
                  dimensional navigation solutions to clinicians in endocardial
                  electrophysiology (and where mutually agreed by the parties in
                  writing, pediatric cardiology and interventional cardiology)
                  by adding to the INTEGRATED CATH LAB (and where applicable,
                  the NEXT GENERATION INTEGRATED CATH LAB defined below) the
                  capability of navigating by utilization of proprietary
                  Siemens' endocardial ultrasound integration technology or by
                  utilization of proprietary Siemens' advanced registration of
                  PRE-operative CT or MRI Imaging, that is registered to the
                  ARTIS dFC FLUOROSCOPY SYSTEM (collectively, "PROPRIETARY
                  SIEMENS REGISTERED IMAGING", as defined in more detail below);

         (ii)     To address the co-development and commercialization of an
                  advanced interventional radiology cath lab ("ADVANCED IR LAB")
                  providing such unique clinical solutions to clinicians in
                  interventional radiology by way of adding specialized features
                  to the INTEGRATED CATH LAB (and where applicable, the NEXT
                  GENERATION INTEGRATED CATH LAB defined below), whether by way
                  of utilization of PROPRIETARY SIEMENS REGISTERED IMAGING or
                  otherwise, as are mutually agreed in writing by the parties in
                  accordance with the terms of this Agreement;

         (iii)    To address the co development by Siemens and Stereotaxis of a
                  version of the NEXT GENERATION NIOBE SYSTEM (defined below)
                  utilizing [***] ("[***] NIOBE SYSTEM") to be incorporated into
                  a next generation of the INTEGRATED CATH LAB ("NEXT GENERATION
                  INTEGRATED CATH LAB");

         (iv)     To increase coordination of marketing, promotions and sales
                  LABs by establishing co-sponsored Exhibition Sites and Centers
                  of Excellence at selected leading electrophysiology and
                  interventional cardiology sites, by increasing

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]

<PAGE>

                                       3

                  coordination of sales force incentives, sales force and
                  customer training and conference presentations and
                  publications;

         (v)      To provide for global first level service by Siemens of LABs;
                  and

         (vi)     to provide for collaboration of the parties in respect of new
                  technologies applicable to LABs by mutual agreement from time
                  to time:

         in the manner set out below.

1. DEFINITIONS

1.1      The terms "NIOBE SYSTEM", ARTIS dFC FLUOROSCOPY SYSTEM", and "COMMON
         USER INTERFACE" mean:

1.1.1    The "NIOBE SYSTEM" means Stereotaxis' digital instrument control system
         and subsequent generations of that system whether sold under NIOBE or
         other trademarks, which allows navigation and control of guidewires,
         catheters and other instruments in the body by external magnetic
         forces. Unless the context requires otherwise, this will be taken to
         include major accessories designed to be used with such system.

1.1.2    The "ARTIS dFC FLUOROSCOPY SYSTEM" means Siemens' ARTIS dFC digital
         cardiology X-ray imaging system and subsequent generations of Siemens
         digital cardiology X-ray system whether sold under ARTIS or other
         trademarks. Unless the context requires otherwise, this will be taken
         to include major accessories designed to be used with such system.

1.1.3    The "COMMON USER INTERFACE" means the common interface developed by the
         parties pursuant to the COLLABORATION AGREEMENT for the integration of
         the NIOBE SYSTEM and the ARTIS dFC FLUOROSCOPY SYSTEM to comprise the
         INTEGRATED CATH LAB.

1.2      The term "INFORMATION" means written and/or oral technical information
         with regard to the components mentioned in Section 1.1 herein above,
         such information being available to one party at any time during the
         term of this Agreement and not resulting from performing DEVELOPMENT
         WORK.

1.3      The term "ADVANCED CARDIOLOGY CATH LAB DEVELOPMENT WORK" means any and
         all development work to be performed by the parties to develop the
         ADVANCED CARDIOLOGY CATH LAB by adding to the INTEGRATED CATH LAB the
         capability of navigating using PROPRIETARY SIEMENS REGISTERED IMAGING,
         in accordance with Section 2 below.
<PAGE>
                                       4

1.4  The term "ADVANCED IR LAB DEVELOPMENT WORK" means any and all development
     work to be performed by the parties to develop the ADVANCED IR LAB, which
     will include (without being limited to) enhanced three dimensional imaging
     capabilities for applications that may include solutions for liver
     embolization and uterus myoma treatment and may additionally include
     applications for interventional neuroradiology including arteriovenous
     malformations and aneurysm.

1.5  The term "NEXT GENERATION NIOBE SYSTEM" means Stereotaxis' next commercial
     release of the NIOBE SYSTEM that has been integrated with a digital
     fluoroscopy system and designed to contain: (i) more compact magnet
     systems; and (ii) a primary set of rotational and other axes of motion for
     the magnets; both of which are contained in enclosed pods that can be
     affixed to secondary, external positioners. [***]

1.6  The term "[***] NIOBE SYSTEM DEVELOPMENT WORK" means any and all
     development work to be performed by the parties (pursuant to agreement
     under Section 2.2(i)) to modify Stereotaxis' NEXT GENERATION NIOBE SYSTEM
     to create an [***] NIOBE SYSTEM that is integrated with the ARTIS dFC
     FLUOROSCOPY SYSTEM.

1.7  The term "DEVELOPMENT WORK" means either of ADVANCED CARDIOLOGY CATH LAB
     DEVELOPMENT WORK, ADVANCED IR LAB DEVELOPMENT WORK or [***] NIOBE SYSTEM
     DEVELOPMENT WORK.

1.8  The term "DEVELOPMENT RESULTS" means any and all results, whether
     patentable or not, in written or oral form, achieved by performing
     DEVELOPMENT WORK.

1.9  The term "NEXT GENERATION INTEGRATED CATH LAB" means the [***] NIOBE SYSTEM
     integrated with the ARTIS dFC FLUOROSCOPY SYSTEM via a common user
     interface and will also include, where applicable, an ADVANCED CARDIOLOGY
     CATH LAB or an ADVANCED IR LAB in which the [***] NIOBE SYSTEM is a
     component.

1.10 The term "LAB" represents an INTEGRATED CATH LAB, an ADVANCED CARDIOLOGY
     CATH LAB, an ADVANCED IR LAB and/or a NEXT GENERATION INTEGRATED CATH LAB.

1.11 The term "PROPRIETARY SIEMENS REGISTERED IMAGING" has the meaning set
     forth in the paragraph (i) of the preamble to this Agreement and
     (notwithstanding anything contained elsewhere in this agreement): (i) will
     not be taken to include registration of output of rotational angiography
     conducted in a cath lab with a cath lab x-ray/fluoroscopy system; (ii)
     will be taken to include registration of such additional imaging
     modalities as is mutually agreed in writing by the parties; (iii) may
     include such advanced registration or integration technology as far as
     owned by Siemens alone or together with partners; and

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]

<PAGE>
                                       5

                  (iv)  will not be taken to include imaging solutions that have
                        become common practice or commonly available in the cath
                        lab industry.

         1.122.   Carrying out of the DEVELOPMENT WORK

         2.1      Details of the DEVELOPMENT WORK are set forth in Annex 1
                  hereto, which may be amended from time to time in writing by
                  the parties.

         2.2      The parties will coordinate and mutually consider within a
                  period to be agreed (but in any event no later than [***] of
                  the Effective Date) the feasibility of their developing and
                  commercializing the [***] NIOBE SYSTEM in accordance with the
                  timetable contemplated in this Agreement. At the end of such
                  period, then either: (i) The parties will agree in writing to
                  proceed with development and commercialization of the [***]
                  NIOBE SYSTEM in accordance with the terms of this Agreement;
                  or (ii) The terms of this Agreement relating to the [***]
                  NIOBE SYSTEM will no longer be of any force or effect.

         2.3      The parties will coordinate and mutually consider within a
                  period to be agreed upon (but in any event no later than [***]
                  of the Effective Date) the clinical solutions to be comprised
                  in and the feasibility of developing and commercializing the
                  ADVANCED IR LAB in accordance with the timetable contemplated
                  in this Agreement. At the end of such period, then either: (i)
                  The parties will agree in writing to proceed with the
                  development and commercialization of the ADVANCED IR LAB in
                  accordance with the terms of this Agreement; or (ii) The terms
                  of this Agreement relating to the ADVANCED IR LAB will no
                  longer be of any force or effect

         2.4      The ADVANCED CARDIOLOGY CATH LAB DEVELOPMENT WORK will be
                  undertaken by the parties in an expeditious fashion and the
                  parties will use all reasonable commercial efforts to achieve
                  completion of such work so as to enable the commercial
                  introduction of the ADVANCED CARDIOLOGY CATH LAB during 2004.
                  The ADVANCED CARDIOLOGY CATH LAB DEVELOPMENT WORK shall be
                  regarded as being completed successfully if ADVANCED
                  CARDIOLOGY CATH LAB fulfills the specifications as agreed
                  upon in accordance with Section 1.1 and when final system
                  testing and readiness for shipment of the system to the
                  customer is achieved.

         2.4.1    Stereotaxis agrees that from the date hereof until the
                  expiration of the period of 12 months following the placement
                  of the first ADVANCED CARDIOLOGY CATH LAB at a customer site
                  or until year end 2005, whichever is the earlier, it will not
                  place my NIOBE SYSTEMs or NEXT GENERATION NIOBE SYSTEMs that
                  are integrated with a third party x-ray imaging system in a
                  manner that incorporates registration to such x-ray imaging
                  system of three dimensional pre-operative imaging so as to
                  provide advanced electrophysiology solutions that are
                  substantially comparable to advanced electrophysiology
                  solutions provided by the ADVANCED CARDIOLOGY CATH LAB by

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]

<PAGE>
                                       6

         reason of integration of PROPRIETARY SIEMENS REGISTERED IMAGING
         pursuant to this Agreement.

2.5      Subject to Section 2.2, the [***] NIOBE SYSTEM DEVELOPMENT WORK will be
         undertaken by the parties in an expeditious fashion and the parties
         will use all reasonable commercial efforts to achieve completion of
         such work so as to enable the commercial introduction of the [***]
         NIOBE SYSTEM during [***]. The [***] NIOBE SYSTEM DEVELOPMENT WORK
         shall be regarded as being completed successfully if NEXT GENERATION
         INTEGRATED CATH LAB fulfills the specifications as agreed upon in
         accordance with Section 1.1 and when final system testing and readiness
         for shipment of the system to the customer is achieved.

2.5.1    Stereotaxis agrees that during the period commencing on the date hereof
         and ending [***] following the placement of the first [***] NIOBE
         SYSTEM at a customer site or, until year end [***] whichever is the
         earlier, it will not place any NEXT GENERATION NIOBE SYSTEMS that are
         integrated with third party x-ray fluoroscopy systems and utilize [***]
         so as to be configured in like manner to the [***] NIOBE SYSTEM.

2.6      Subject to Section 2.3, the ADVANCED IR LAB DEVELOPMENT WORK will be
         undertaken by the parties in an expeditious fashion and the parties
         will use all reasonable commercial efforts to achieve completion of
         such work so as to enable the commercial introduction of the ADVANCED
         IR LAB during 2004. The ADVANCED IR LAB DEVELOPMENT WORK shall be
         regarded as being completed successfully if the ADVANCED IR LAB
         fulfills the specifications as agreed upon in accordance with Section
         1.1 and when final system testing and readiness for shipment of the
         system to the customer is achieved.

2.7      Stereotaxis agrees that during the period commencing on the date hereof
         and ending 12 months following the placement of the first ADVANCED IR
         LAB at a customer site or until year end 2005, whichever is the
         earlier, it will not place any NIOBE SYSTEMs or NEXT GENERATION NIOBE
         SYSTEMs that are integrated with a third party x-ray imaging system
         and provide proprietary solutions that are substantially comparable to
         the proprietary advanced interventional radiology solutions provided
         by the ADVANCED IR CATH LAB. Each party shall bear the costs incurred
         by such party for its efforts under or in connection with the
         DEVELOPMENT WORK.

2.8      Each party, insofar as it lawfully may, shall make available to the
         other within a reasonable period of time following the Effective Date
         of this Agreement, and from time to time during the carrying out of
         the DEVELOPMENT WORK its INFORMATION and DEVELOPMENT RESULTS insofar
         as it considers such INFORMATION and DEVELOPMENT RESULTS necessary for
         the other party for carrying out the

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]

<PAGE>
                                       7

         DEVELOPMENT WORK. Disclosure of INFORMATION and DEVELOPMENT RESULTS
         will be effected without charges to the receiving party.

2.9      The DEVELOPMENT WORK will be carried out in close cooperation between
         the parties and in a joint effort to keep cost and expenditures to a
         minimum.

2.9.1    Each party undertakes to carry out the DEVELOPMENT WORK as stipulated
         in this Agreement.

3.       CERTAIN ITEMS REGARDING LAB PLACEMENTS AND SALES

3.1      The parties' goal is to achieve installation of [***] and the parties
         will coordinate and use all reasonable commercial efforts to achieve
         these goals. Siemens and Stereotaxis will each provide their components
         of LABs to customers on commercially reasonable terms and on a
         competitive basis and in timely fashion and together with the provision
         of service for LABs as provided for herein. For purposes of this
         Section 3.1, components will be offered on a competitive basis where
         provided on terms that are: (i) where applicable, reasonably comparable
         to the basis upon which such components or their equivalent are
         provided to customers for placements that are not integrated in LABs;
         or (ii) for components of a type that are unique to LABs, based on
         margins that are reasonably comparable margins generally achieved on
         other components of LABs.

3.2      Stereotaxis will not make available to third parties via integration of
         the NIOBE SYSTEM or otherwise any proprietary Siemens PROPRIETARY
         SIEMENS REGISTERED IMAGING. Section 6.4 shall apply accordingly.

3.3      Stereotaxis may integrate the NEXT GENERATION NIOBE SYSTEM with a third
         party X-ray system in like manner to the [***] NIOBE SYSTEM, provided
         that Stereotaxis will provide Siemens with reasonable compensation for
         Siemens' licensing to third party vendors any Siemens' intellectual
         property relating to electrical and mechanical integration know how (in
         the version as available at and used by Siemens) upon its transfer to
         such third party vendors that may be required to permit such third
         party integration. Siemens agrees that it will so license Stereotaxis
         and/or third parties on request to enable them to make, use and sell
         such third party integrated NEXT GENERATION NIOBE SYSTEMs or components
         thereof or modifications thereof based on such compensation. The value
         of any such Siemens' intellectual property used with or by third party
         vendors will be mutually agreed by Siemens and Stereotaxis based on
         reasonable commercial terms. The parties will, no later than [***]
         after the date of this Agreement confer in good faith and mutually
         agree a final determination of the level of such compensation.

3.4      As appropriate, customer sales approach in respect of LABs can be
         jointly or separately by each party. Each party shall inform the other
         promptly of any potential customer and each party agrees to fully
         cooperate with the other in respect of reasonable requests for

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]
<PAGE>
                                      8

coordination of customer sales efforts, provided that the parties continue to
maintain distinct and separate business and sales operations and identities and
that the distinct separation between the customer's purchase of components from
Stereotaxis and from Siemens will be evident to the customer:

         (i)      In respect of INTEGRATED CATH LABs, as set forth in the
                  COLLABORATION AGREEMENT;

         (ii)     In respect of NEXT GENERATION INTEGRATED CATH LABs, until such
                  time as any NEXT GENERATION NIOBE SYSTEM that is integrated
                  with a third party X-ray system in like manner to the [***]
                  NIOBE SYSTEM is commercially released, or otherwise as
                  mutually agreed in writing;

         (iii)    In respect of ADVANCED CARDIOLOGY CATH LABs and ADVANCED IR
                  LABs, until such time as either party provides the other with
                  written notice to the contrary.

3.5      For placements of LABS, sales brochures, bid specification and
customer payment will be made in a way that a distinct separation between the
Stereotaxis components and Siemens components is evident to the customer.

         (i)      Notwithstanding the above, there is a joint document for
                  room planning and installation instructions.
         (ii)     Siemens will provide to the customer project management on
                  site addressing room preparation, shipment and installation.
         (iii)    Contracts with customers will be signed by each party for
                  their respective components to be delivered.
         (iv)     Each party will manufacture, warrant, sell and deliver its
                  components of such LABs in accordance with reasonable industry
                  practices and will not cease to so manufacture, warrant, sell
                  and deliver such components based on customer purchase orders
                  without 18 months prior notice to the other party.

3.6      Stereotaxis and Siemens may mutually agree upon cross-incentive
programs to enhance sales force focus on placement on LABs

3.7      For placements of ADVANCED CARDIOLOGY CATH LABs, Stereotaxis and
Siemens will cooperate to:

         (i)      Coordinate salesforce and customer training activities;

         (ii)     Confer and consider in good faith arrangements whereby Siemens
                  would distribute [***] NIOBE SYSTEMs on reasonable commercial
                  terms;

         (iii)    Coordinate and facilitate publications and conference
                  presentations as mutually agreed;
         (iv)     Coordinate and establish a minimum of two Exhibition Sites
                  at Barnes in St. Louis and at such other site as mutually
                  agreed (likely at St. Georg in Hamburg) [***]

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]

<PAGE>

                                       9

                           [***] The parties will ensure that at the time of
                           installation and thereafter that their components
                           provided to such LAB have the most up to date
                           software releases installed that are designed for use
                           with such components. Such demonstration site will
                           remain installed until such time as mutually agreed
                           by the parties. [***] and

                  (v)      Coordinate and establish Center of Excellence
                           Clinical Sites targeting key interventional hospitals
                           such as [***] and such other sites as are mutually
                           agreed, the object being to promote the capabilities
                           of the integrated systems and to establish new
                           clinical solutions.

                  Further details on the sales cooperation will be agreed to by
                  a "collaborative sales working group" to be established after
                  the signing of this Agreement, the object being to promote
                  sales and promotions cooperation between the parties while
                  continuing to maintain distinct and separate business and
                  sales operations and identities.

4.       LOGISTICS

For placements of LABs, Stereotaxis as well as Siemens will ship directly to
the customer site. Time schedule is coordinated by the Siemens and Stereotaxis
project managers. The first unit of any LAB will be tested in Siemens AX before
shipment to the customer to assure successful integration and system
performance. The number of units that have to pass the compatibility test after
the first units testing will be defined separately and mutually agreed. Further
details on logistics will be agreed to by the collaborative logistics working
group established pursuant to the Collaboration Agreement, which will also be
used to coordinate logistics issues arising under this Agreement.

5.       INSTALLATION AND SERVICE

5.1      For installations of LABs, at least one Stereotaxis person will be on
         site at the customer facility, at Stereotaxis cost and expense, at the
         time of installation. Siemens will support the installation of
         Stereotaxis components to Siemens' system.

5.2      Service of LABs on site will be done by Siemens in accordance with a
         service contract between the Siemens and Stereotaxis, on commercially
         reasonable terms to be mutually agreed or, where applicable, in
         accordance with existing service contracts in respect of LABs that are
         already in place.

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]

<PAGE>
                                       10

         Such service will include Stereotaxis' components of LABs. To enable
         Siemens to perform service Stereotaxis shall provide Siemens at no cost
         with INFORMATION necessary for Siemens to perform service on
         Stereotaxis' components and shall train at no cost to Siemens a
         reasonable number of Siemens' specialists in the service of
         Stereotaxis' components. Furthermore, Stereotaxis and Siemens shall
         cooperate to provide service call center support as well as spare
         parts in respect of LABs.

         Details regarding service of LABs including but not limited to response
         time and spare part logistics, will be agreed to by the collaborative
         service working group established pursuant to the Collaboration
         Agreement, which will also be used to coordinate service issues arising
         under this Agreement.

         Regarding service for LABs, Siemens agrees to provide Stereotaxis with
         no less than 24 months written notice of termination of such service.
         Details regarding the installation will be separately agreed upon.

6.       SECRECY

6.1      Either Party expressly undertakes to retain in confidence, to protect
         with the same degree of care used in protecting its own INFORMATION and
         not to use for other purposes than contemplated by this Agreement or to
         disclose to any third party all INFORMATION in a written or other
         tangible form supplied by the other Party in relation to this Agreement
         and clearly marked as being "Confidential". Oral INFORMATION of a Party
         that is confidential and is restricted in use shall be reproduced in
         writing marked as being "Confidential" and sent to the other Party
         within one (1) month after its communication to the other Party. The
         receiving Party agrees to restrict access of such Confidential
         information to employees and agents who have a need to know pursuant to
         their scope of employment or agency arrangement and further agrees to
         instruct its employees and agents having access to such Confidential
         INFORMATION of receiving Party's confidentiality obligations.

6.2      The aforementioned obligation shall not apply to INFORMATION that is:

6.2.1    published or otherwise made available to the public other than by a
         breach of this Agreement; or

6.2.2    rightfully received by a Party from a third party without confidential
         obligation; or

6.2.3    shown through competent evidence to have been independently developed
         by the other Party without reference to the INFORMATION; or to have
         been known by the receiving Party prior to its first receipt of such
         INFORMATION from the other Party; or

6.2.4    required to be disclosed pursuant to a legal, judicial, or
         administrative proceeding, or by law; or
<PAGE>
                                       11

6.2.5    approved for disclosure by prior written consent of an authorized
         corporate representative of the disclosing Party.

6.3      The aforementioned obligations do apply accordingly with regard to
         DEVELOPMENT RESULTS of the other Party.

6.4      The non-disclosure obligations set forth in this Section 6 shall
         survive expiration or termination of this Agreement by three (3) years.

6.5      Press releases or other information on the conclusion/content of this
         Agreement shall only be made available to third parties/press agencies
         (other than disclosure by Stereotaxis in relation to raising private
         equity funds or as legally required pursuant to an initial public
         offering of equity) with the prior written consent of the other Party
         hereto such consent not to be unreasonably withheld.

7.       WARRANTIES AND LIMITATION OF LIABILITIES

7.1      Provided it complies with its development obligations pursuant to
         Section 2, no party shall be liable towards the other party in the case
         that the DEVELOPMENT WORK cannot be successfully completed.

7.2      The sole obligation of each party with respect to its INFORMATION and
         DEVELOPMENT RESULTS shall be to forward same to the other party as
         provided in this Agreement, and, to correct errors that might have
         occurred in this INFORMATION and DEVELOPMENT RESULTS without undue
         delay after such errors become known to the party which forwarded the
         relevant INFORMATION or DEVELOPMENT RESULTS.

7.3      THE WARRANTIES SET FORTH IN THIS SECTION 7 APPLY TO ALL INFORMATION AND
         DEVELOPMENT RESULTS LICENSED OR KNOWINGLY DISCLOSED HEREUNDER AND ARE
         IN LIEU OF ALL WARRANTIES EXPRESS OR IMPLIED INCLUDING WITHOUT
         LIMITATION THE WARRANTIES THAT INFORMATION AND DEVELOPMENT RESULTS CAN
         BE USED WITHOUT INFRINGING STATUTORY AND OTHER RIGHTS OF THIRD PARTIES.

7.4      Warranties and liabilities regarding the delivery of the components of
         each party shall be governed by the contracts between each such party
         and the respective customer.

7.5      Should a customer forward a warranty or any liability claim - including
         product liability claims - to either party then such party shall be
         responsible for such claims only to the extent such claims relate to
         the components such party has delivered to the customer. Each party
         shall indemnify and hold the other party harmless from any claim,
         costs,
<PAGE>
                                       12

     expenses, and damages resulting from such claims if the claims relate to
     components delivered by the respective other party, provided however that
     the one party

     a) notifies the other party of such claim, dispute or proceeding without
     undue delay,
     b) does not admit liability on the claims,
     c) provides the other party with the sole authority -- as far as legally
     possible -- to defend and settle such claim, dispute, or proceeding with
     counsel of its choice (the other party may participate at its costs with
     counsel of its choice), and
     d) cooperates as reasonably requested by the other party.

7.6  Each party shall secure and maintain, for the useful life of the components
     delivered by it, a product liability insurance policy full coverage for
     product liability exposure (including negligence and strict liability) to
     third parties anywhere in the world for any defects whatsoever (such as
     design-, manufacture-, instruction defects) resulting from defects in the
     components supplied hereunder in the minimum of US [***]. At either party's
     request the other party shall prove compliance with the obligation to
     insure as herein stated.

7.7  NEITHER PARTY SHALL HAVE ANY LIABILITY TO THE OTHER FOR ANY CONSEQUENTIAL,
     INCIDENTAL, PUNITIVE, INDIRECT OR SPECIAL DAMAGES BY REASON OF ANY ACT OR
     OMISSIONS OR ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS
     USE OR OPERATION, INCLUDING BUT WITHOUT LIMITATION ANY LOSS OF USE, LOSS
     OF INFORMATION AND DATA, LOST REVENUES, LOST PROFITS, COSTS OF CAPITAL,
     COSTS OF SUBSTITUTE PRODUCTS, FACILITIES, OR SERVICES, COSTS OF
     REPLACEMENT POWER, COST ASSOCIATED WITH DOWN TIME, AND ANY SIMILAR AND
     DISSIMILAR LOSSES, COSTS AND DAMAGES.

7.8  The provisions of this Section 7. shall survive any termination of this
     Agreement.

8.   DEVELOPMENT RESULTS, INFORMATION AND RIGHTS THEREUNDER

8.1  The DEVELOPMENT RESULTS shall, at the time they are made, become the sole
     property of such party, the employees of which have generated the
     respective DEVELOPMENT RESULTS. DEVELOPMENT RESULTS made jointly by
     employees of both parties shall become the joint ownership of both
     parties. In case DEVELOPMENT RESULTS consist of joint inventions, the
     parties shall agree on whether, and if so, where and at whose cost and
     expense statutory protection rights will be filed for. Joint DEVELOPMENT
     RESULTS, including any and all statutory protection issuing thereon, if
     any, may be used by each party in its field of activities.

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]
<PAGE>

                                      13

8.2      Under its INFORMATION and DEVELOPMENT RESULTS each party hereby grants
         to the other party the non-exclusive, non-transferable, royalty free
         right to use same during the term of this Agreement for the purpose of
         carrying out the DEVELOPMENT WORK and thereafter to the extent
         necessary for the exploitation of the DEVELOPMENT RESULTS of the other
         party or of the joint DEVELOPMENT RESULTS.

8.3      Notwithstanding ownership under DEVELOPMENT RESULTS and the rights
         granted hereunder, the exclusivity granted under Section 3.2 shall
         prevail.
8.4      The stipulations of this Section 8. shall survive any termination of
         this Agreement.

9.       JAPANESE MARKET DEVELOPMENT

         Pursuant to an Agreement between the parties of even or approximate
         date herewith, the parties intend to collaborate in respect of Japanese
         market development for LABs. Details will be agreed upon in a separate
         agreement between Stereotaxis and the Siemens affiliated company in
         Japan.

10.      SIEMENS INVESTMENT IN STEREOTAXIS

         This Agreement will be of no force or effect unless and until Siemens'
         investment of $10 million in Stereotaxis Series E Preferred Stock is
         closed.

11.      TERM AND TERMINATION

11.1     This Agreement shall become effective on the date it is signed by both
         parties (Effective Date) and is terminated or expires in accordance
         with the terms hereof, in any event no later than 36 months after
         becoming effective. No later than 12 months before the end of this 36
         month period, both parties will commence in good faith negotiations on
         extending the collaboration.

11.2     This Agreement may be terminated at any time by the one party by
         giving of not less than four weeks' prior written notice to the other
         party.

         -  if the other party hereto is declared bankrupt or otherwise cannot
            fulfill its financial obligations; or

         -  if the other party hereto substantially defaults in the performance
            of this Agreement and does not remedy the default within 4 weeks
            after receipt of a relevant written request of the one party; or

         -  if the other party comes under direct or indirect control or
            direction of any other entity competing with the one party.
<PAGE>

                                       14

11.3     Sections 6, 7, 8, 11, 12 shall survive termination of this Agreement.

12.      ARBITRATION

12.1     Any differences or disputes arising from this Agreement or from
         agreements regarding its performance shall be settled by an amicable
         effort on the part of both parties to the Agreement. An attempt to
         arrive at a settlement shall be deemed to have failed as soon as one of
         the parties to the Agreement so notifies the other party in writing.

12.2     If an attempt at settlement has failed, the disputes shall be finally
         settled under the Rules of Conciliation and Arbitration of the
         International Chamber of commerce in Paris (Rules) by three arbitrators
         appointed in accordance with the Rules.

12.3     The place of arbitration shall be Berne, Switzerland. The procedural
         law of this place shall apply where the Rules are silent.

12.4     The arbitral award shall be substantiated in writing. The arbitral
         tribunal shall decide on the matter of costs of the arbitration.

13.      SUBSTANTIVE LAW

         All disputes shall be settled in accordance with the provisions of this
         Agreement and all other agreements regarding its performance, otherwise
         in accordance with the substantive law in force in the Canton of Berne,
         Switzerland, without reference to other laws.

14.      MISCELLANEOUS

14.1     This Agreement may not be released, discharged, abandoned, changed or
         modified in any manner, except by an instrument in writing signed on
         behalf of each of the parties hereto by their duly authorized
         representatives.

14.2     The failure of any party hereto to enforce at any time any of the
         provisions of this Agreement shall in no way be construed to be a
         waiver of any such provision, nor in any way to affect the validity of
         this Agreement or any part thereof or the right of any party thereafter
         to enforce each and every such provision. No waiver of any breach of
         this Agreement shall be held to be a waiver of any breach of this
         Agreement shall be held to be a waiver of any other or subsequent
         breach.

<PAGE>
                                       15

14.3 All notices or other communications required or permitted hereunder with
     regard to the interpretation, validity, etc. of the Agreement shall be in
     writing and shall be given by certified mail addressed, if to Stereotaxis

     Stereotaxis, Inc.
     Attn. Chief Executive Officer
     Atten Chief Financial Officer
     4041 Forest Park AVE.
     St. Louis, MO 63108
     U.S.A.

     and, if to Siemens:
     Siemens Aktiengesellschaft
     Legal Services Med
     Werner von Siemens Str. 50
     91052 Erlangen
     Germany

     or to such other address that the parties might identify to each other for
     this purpose and with reference to this Agreement.

14.4 Subject to Section. 6.5 above, no party hereto shall issue any press
     release or public announcement or otherwise divulge the existence of this
     Agreement or the transactions contemplated hereby without the prior
     approval of the other party hereto.

14.5 This Agreement shall be binding upon and inure to the benefit of the
     parties hereto and the successors or assigns of the parties hereto.

14.6 Titles and headings to Sections herein are inserted for the convenience or
     reference only and are not intended to be a part of or to affect the
     meaning or interpretation of this Agreement.

14.7 This Agreement may be executed in one or more counterparts, all of which
     shall be considered one and the same agreement.

IN WITNESS WHEREOF, the parties have executed these presents on the dates
specified below.
<PAGE>
                                       16

St. Louis,  27 May 2003                 Forchheim, 27.05.2003
          ------------------                      ------------------
Stereotaxis, Inc.                       Siemens Aktiengesellschaft

      /s/ BEVIL J. HOGG                         illegible
----------------------------            ----------------------------

                                                illegible
<PAGE>
                                       17

ANNEX 1

DEVELOPMENT WORK

ADVANCED CARDIOLOGY CATH LAB DEVELOPMENT WORK RELATING TO PROPRIETARY SIEMENS
REGISTERED IMAGING

Subject to the results of determining the feasibility of this project, image
registration and integration of PROPRIETARY SIEMENS REGISTERED IMAGING that
will include:

         1.       Allowing target based navigation from a CT or MRI
                  pre-operative image that is registered to the fluoroscopy
                  output. Included in this approach would be a fluoroscopy image
                  that is registered to a pre-operative image which in turn may
                  be registered to a Biosense CARTO map

Additional consideration will be given as to include navigational control using
endocardial ultrasound

Common Stereotaxis/Siemens image integration specifications will be defined in
the "Requirement Specification". This document will be jointly created and will
be reviewed and released by both parties. The image integration will be tested
in a "System test" applied to both the Stereotaxis and Siemens components of
the ADVANCED CARDIOLOGY CATH LAB. Results have to be documented and are the
base for a joint release for shipment to customers. Each of the two parties is
responsible for their own component. Details will be agreed by a "collaborative
3D engineering working group" to be established after signing of this Agreement.

[***] NIOBE SYSTEM DEVELOPMENT WORK

Subject to the results of determining the feasibility of this project, common
Stereotaxis/Siemens specifications for the [***] configuration of the NEXT
GENERATION INTEGRATED CATH LAB will be defined in the "Requirement
Specification". This document will be jointly created and will be reviewed and
released by both parties. The [***] NIOBE SYSTEM configuration and the NEXT
GENERATION INTEGRATED CATH LAB will be tested in a "System test" applied to both
the Stereotaxis and Siemens components. Results have to be documented and are
the base for a joint release for shipment to customers. Each of the two parties
is responsible for their own component. Details will be agreed by a
"collaborative [***] configuration working group" to be established after
signing of this Agreement.

ADVANCED IR LAB DEVELOPMENT WORK

Subject to the results of determining the feasibility of this project, common
Stereotaxis/Siemens specifications for unique clinical solutions in
interventional radiology comprised in the ADVANCED IR LAB will be defined in
the "Requirement Specification". This document will be

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]
<PAGE>
                                       18

jointly created and will be reviewed and released by both parties. The ADVANCED
IR LAB configuration will be tested in a "System test" applied to both the
Stereotaxis and Siemens components. Results have to be documented and are the
base for a joint release for shipment to customers. Each of the two parties is
responsible for their own component. Details will be agreed by a "collaborative
ADVANCED IR LAB configuration working group" to be established after signing of
this Agreement.<PAGE>
                                                                   Exhibit 10.19

                         THIRD PARTY SERVICES AGREEMENT

     This THIRD PARTY SERVICES AGREEMENT (the "Agreement") is made as of this
5th day of August, 2002 ("Effective Date") by and between STEREOTAXIS, Inc., a
Delaware corporation with an address at 4041 Forest Park Ave., St. Louis,
Missouri 63108 (hereafter referred to as "Stereotaxis") and SIEMENS MEDICAL
SOLUTIONS USA, Inc., a Delaware corporation with an address at 51 Valley Stream
Parkway, Malvern, PA 19355 (hereafter referred to as "Siemens").

                                   WITNESSETH:

     WHEREAS, Stereotaxis and Siemens Aktiengesellschaft, Medical Solutions,
Forchheim, Germany, have entered into a Collaboration Agreement dated June 8,
2001 ("Collaboration Agreement"), with respect to the integration of
Stereotaxis' magnetic guiding component (NIOBE) as well as its magnetic holding
component (ASSERT Aneurysm) (collectively, the "Stereotaxis Products") with
Siemens' Cardiac, Angio and Neuro X-Ray and imaging components (collectively,
the "Siemens Products"); and

     WHEREAS, Stereotaxis will enter into agreements with customers for the
sale, installation and servicing of the Stereotaxis Products; and

     WHEREAS, Stereotaxis has determined that it may be more cost-efficient for
Siemens to provide certain services with respect to the Stereotaxis Products in
conjunction with the services that Siemens provides for the Siemens Products;
and

     WHEREAS, Stereotaxis wishes to retain Siemens to provide certain site
planning, project management and equipment maintenance and support services with
respect to the Stereotaxis Products, which Stereotaxis is obligated to provide
under the terms of agreements with its customers;

     NOW, THEREFORE, in consideration of the premises and mutual covenants set
forth herein, the parties agree as follows:

     1.  SCOPE of AGREEMENT. This Agreement has been entered into by the parties
in order to implement some of the requirements of the Collaboration Agreement
and will be read subject to the terms of the Collaboration Agreement. Subject to
the terms and conditions of this Agreement, Stereotaxis hereby engages Siemens
and Siemens hereby accepts such engagement to provide site planning, project
management and equipment maintenance and support services with respect to the
Stereotaxis Products in accordance with the terms of this Agreement and further
in accordance with the terms and conditions set forth in one or more Purchase
Orders to be issued by Stereotaxis to Siemens in accordance with Section 5
hereof (the "Services").

     2.  TERM. The term of this Agreement shall be for a period commencing on
the Effective Date and ending on December 31, 2004, unless sooner terminated in
accordance with the terms of this Agreement. The term of this Agreement may be
extended for additional periods of one (1) year each upon mutual written consent
of the parties. In the event that Stereotaxis has issued one or more Purchase
Orders to Siemens in accordance with Section 5 of this Agreement and the
Services to be performed by Siemens pursuant to the terms thereof extend beyond
the termination of this Agreement, then Siemens shall continue to act under the
terms of this Agreement until all Services pursuant to any outstanding Purchase
Order(s) have been completed.

     3. PRICING. Prices for the Services are as set forth in Exhibit A
(captioned "Pricing for Services"). Siemens shall provide the Services at the
Prices specified in Exhibit A as ordered by Stereotaxis pursuant to Purchase
Orders issued pursuant to Section 5 of this Agreement.

<PAGE>

     4.  PAYMENT TERMS. Siemens shall invoice Stereotaxis for its Services on a
monthly basis. Payment terms are net thirty (30) days from the date of the
invoice. Past due amounts shall bear interest at the rate of 1 1/2% per month
unless subject to bona fide dispute. If Stereotaxis disputes any invoice, it
must notify Siemens in writing within ten (10) days of receipt of the invoice
and must pay the undisputed portion of the invoice in accordance with the terms
of this Agreement. In the event it is determined that the disputed amount is
owed to Siemens, then Stereotaxis shall pay interest on such amount at the rate
set forth of 0.7% per month, which interest shall accrue from the date such
payment was originally due.

     5.  ORDERING OF SERVICES. Siemens agrees to provide the Services described
herein, at such locations and times and in accordance with the specific
requirements set forth in one or more purchase orders ("Purchase Orders") to be
issued by Stereotaxis from time to time during the term of this Agreement and
directed to the attention of William Paines at the Siemens Uptime Service Center
Processing Department (or to such other individual who is designated by
Siemens). Purchase Orders shall refer to and indicate that they are being
submitted subject to the terms and conditions of this Agreement. All Purchase
Orders submitted under this Agreement shall be governed and controlled by the
conditions of this Agreement. In the event of any inconsistency between the
terms of this Agreement and the terms of a specific Purchase Order, the terms of
the Agreement shall prevail.

     6.  TERMINATION.

     (a) It shall constitute a default under the Agreement, with the
corresponding right of termination as stated below, if any of the following
shall occur:

         (i)  In the event of a material violation by a party of any provision
              of this Agreement (the non-payment of undisputed monies due to
              Siemens shall constitute a material violation of the Agreement)
              which violation continues uncured for a period of thirty (30) days
              after written notice to the other party specifying such violation,
              then the Agreement may be immediately terminated by the non-
              breaching party.

         (ii) In the event a party makes an assignment for the benefit of
              creditors, files a voluntary petition in bankruptcy, is
              adjudicated insolvent or bankrupt, a proceeding is filed against
              said party to declare said party a bankrupt and said proceeding is
              not dismissed within thirty (30) days, or said party commences
              any proceeding under any reorganization, arrangement, readjustment
              of debt or similar law or statute of any jurisdiction, then this
              Agreement may be terminated by the other party on five (5) days
              written notice.

     (b) In addition, either party may terminate this Agreement by giving thirty
(30) days prior written notice to the other party in the event that the
obligations in respect of the provision of service to Stereotaxis pursuant to
the Collaboration Agreement expire or terminate, in which case Siemens will
continue to provide through the effective date of termination any Services
accepted and acknowledged prior to its receipt of Stereotaxis' notice or the
date of its notice of termination, and Stereotaxis will accept and pay for all
such Services in accordance with the terms of this Agreement.

     (c) Any termination of this Agreement shall not affect any obligations that
accrued prior to the effective date of termination.

     7.  COOPERATION. The parties will use their reasonable best efforts to
effectuate the purposes of this Agreement and shall cooperate with each other
respecting the same. Specifically, the parties shall cooperate in reviewing and
determining the desired performance level of each item of equipment covered by
this Agreement. Although Siemens shall assume primary responsibility for
assembling the service documentation, Stereotaxis and Siemens agree to cooperate
in this effort. Further, equipment performance and cost analysis will be
reviewed semi-annually and any changes to the Services may be discussed. Each
site may be reviewed and evaluated at this time.

                                       2

<PAGE>

     8.  FORCE MAJEURE. Siemens will not be liable for any failure to fulfill
its obligations under this Agreement due to causes beyond its reasonable control
and without its fault or negligence including, but not limited to, governmental
laws and regulations, acts of God or the public, war or other violence, acts of
terrorism, civil commotion, blockades, embargoes, calamities, floods, fires,
earthquakes, explosions, accidents, storms, strikes, lockouts, work stoppages,
labor disputes, or unavailability of labor, raw materials, power or supplies. In
addition, in the event of any determination pursuant to the provisions of a
collective bargaining agreement preventing or hindering the performance of any
of the obligations of Siemens under this Agreement, or determining that the
performance of any such obligations violates provisions of that collective
bargaining agreement, or in the event a trade union, or unions, otherwise
prevents Siemens from performing any such obligations, then Siemens shall be
excused from the performance of such obligations unless Stereotaxis makes all
required arrangements with the trade union, or unions, to permit Siemens to
perform the work. Any additional costs incurred by Siemens that are related to
such arrangements made by Stereotaxis in respect of such labor dispute(s) shall
be paid by Stereotaxis.

     9.  DEVELOPMENT OF A JOINT PLANNING GUIDE. Stereotaxis shall provide
reasonably sufficient information to jointly develop with Siemens a
site-planning guide for use in preparing customer sites to accept the
Stereotaxis Products. This activity shall consist of reviewing the AXIOM Artis
dFC planning guide 100.891.01 and developing specifications, drawings and
verbiage to describe the required room construction for the Stereotaxis
Products. This data and information shall be incorporated into a joint
site-planning guide and issued by Siemens as a released document with an
assigned Siemens document number. The information to be provided shall include,
but not be limited to, the following:

     o   Structural requirements including:

         o   Component weights and centers of gravity

         o   Desired anchoring methods for the following floor types:

             o   Slab on grade

             o   Screed floors

             o   Computer flooring

             o   Through bolting

     o   Electrical requirements including:

         o   Power specification(s)

         o   Power Distribution

         o   Cable types and lengths including a connection diagram with fixed
             points

         o   Cable separation requirements, if any

         o   Conduit sizes required

     o  Environmental requirements including:

         o   Temperature and humidity specification

         o   Temperature and humidity gradients

         o   Heat dissipation of components

         o   Cabinet airflow

         o   Noise

         o   Temperature & Humidity specifications for transport and storage

     o  Room Planning

         o   Minimum and recommended room sizes

         o   Movement ranges of equipment

         o   Service Access

         o   Detailed drawings of equipment sizes

         o   Details of magnetic shielding options

     o  Equipment Transportation & Delivery

         o   Requirements for equipment ingress, weights, sizes, special
             precautions, etc.

         o   Details of pre-installations kit and required work by the
             contractor

     10. CREATION OF SITE PLANS.

     (a) SIEMENS' RESPONSIBILITIES. Siemens shall create site plans for customer
installations that include details of room preparation requirements for both the
Stereotaxis Products and the Siemens

                                       3
<PAGE>

Products. These site plans shall be based upon the information provided in the
joint site-planning guide. Siemens shall provide to Stereotaxis details of
turnaround commitments for specific site planning drawings. Siemens shall
provide the estimated amount of extra work (hours) for each site plan over and
above those required in respect of the Siemens Products when including details
for the Stereotaxis Products. Based upon this estimate, the parties shall
negotiate the compensation to be paid to Siemens by Stereotaxis for these
services, which shall be on a time basis at the rate set forth in Exhibit A.
Siemens will use its best efforts to provide Preliminary plans or revisions to
Preliminary plans within a 7 calendar day turnaround time. Siemens will use its
best efforts to provide final plans or revisions to final plans within a 21
calendar day turnaround time.

     (b) STEREOTAXIS' RESPONSIBILITIES. Until such time as Siemens and
Stereotaxis agree upon site planning proficiency, Stereotaxis will review each
site plan involving Stereotaxis Products and will not unreasonably withhold its
approval of same.

     11. PROJECT MANAGEMENT OF THE ROOM PREPARATION.

     (a) SIEMENS' RESPONSIBILITIES. Siemens' project managers shall coordinate
the site construction of the room for both the Stereotaxis Products and the
Siemens Products. Siemens' project managers shall provide Stereotaxis with
weekly updates on current construction projects via e-mail. Should Stereotaxis
choose to initiate visits to a customer site during the construction process,
Siemens' project managers shall assist in facilitating these visits. Siemens'
project managers shall furnish a project timeline for each construction project
including projected installation start dates and such timelines shall be
consistent to the extent reasonably feasible with the installation start dates
agreed to at the time of issuance by the relevant customer of purchase orders to
Stereotaxis and Siemens for the Stereotaxis Products and the Siemens Products.
This timeline shall be updated regularly by Siemens' project managers (no less
than monthly). Siemens shall provide the estimated amount of extra work (hours)
for each site's project management activities over and above those required in
respect of the Siemens Products. Based upon this estimate, the parties shall
negotiate the compensation to be paid to Siemens by Stereotaxis for these
services, which shall be on a time basis at the rate set forth in Exhibit A.

     (b) STEREOTAXIS' RESPONSIBILITIES. Stereotaxis will visit each site one
time at the completion of the site construction to verify that the room is
correctly prepared. Siemens and Stereotaxis will mutually determine if
additional Stereotaxis visits are to be made during the construction phase.
Stereotaxis will provide technical support to Siemens' project managers as
reasonably required. Stereotaxis will provide a dedicated telephone number for
service related issues. Stereotaxis will track all questions and develop a
frequently asked questions list for distribution to Siemens' personnel and
inclusion in the site-planning guide.

     12. PRE-INSTALLATION MATERIALS/DEVELOPMENT OF PRE-INSTALLATION KIT.
Stereotaxis will develop a pre-installation kit for use prior to equipment
delivery. This kit will comprise the following:.

    o  Alignment jig for locating Niobe floor bolt locations relative to the
       AXIOM Artis dFC system.

    o  All items that can be installed prior to equipment delivery such as floor
       plates, rotational tracks, etc.

The pre-installation kit shall be available for shipment to the customer site as
requested by Siemens' project manager. For the first 5 systems installed, a
Stereotaxis service representative shall visit the site to aid in accurate
installation of the pre-installation kit. Detailed instructions on the
use/installation of the pre-installation kit shall be provided by Stereotaxis in
both English and German.

        13. INSTALLATION SERVICES. Stereotaxis, where commercially feasible,
will contract with the same subcontractor that Siemens uses for the mechanical
installation and cabling part of the equipment installation. Stereotaxis will
provide adequate training and documentation for the subcontractor to perform
these duties in accordance with the required specifications. Stereotaxis will
also provide a field service engineer on site to complete power on, system
verification and calibration. Siemens' customer service engineer ("CSE") shall
be available on site for the duration of this phase for on site training.

                                       4

<PAGE>

     14.  WARRANTY/SUPPORT SERVICES.

     (a) Siemens' CSEs will provide front line (first call) support for the
Stereotaxis Products during the term of this Agreement, including the product
warranty period (generally one year from the date of installation).

     (b) Subject to Section 14(f) below, Siemens will provide the following
break/fix services during the term of this Agreement: (i) initial call receipt
by Siemens UPTIME Service Center (available 24/7 hours); (ii) remote diagnosis,
if available, by Siemens technical support; (iii) dispatch of Siemens CSE to
customer site; (iv) diagnosis of problem and corrective action (no part call);
(v) ordering of necessary part(s), removal and replacement of parts, calibration
and corrective action; (vi) escalation of problems to Stereotaxis that are
beyond the level of training provided to Siemens' CSEs; and (vii) continued
on-site support as required to assist the Stereotaxis field service engineer and
to resolve the customer problem.

     (c) Siemens will install all software and hardware updates as released by
Stereotaxis.

     (d) Siemens will provide reporting of any complaints related to
Stereotaxis' Products to Stereotaxis.

     (e) Reimbursement to Siemens for these services will be on a time basis at
the rates set forth in Exhibit A attached hereto.

     (f) Prior to Siemens dispatching a Siemens CSE to a customer site, as
described in Section 14(b)(iii) above, Siemens shall notify Stereotaxis'
technical support staff and obtain its approval to render such service. In the
event that Stereotaxis fails to respond to Siemens within one (1) hour of such
notification, then Siemens will proceed to render such services. If Siemens
dispatches a CSE to the customer site before receiving the approval of
Stereotaxis or, in the absence of any such approval, before the expiration of
the one (1) hour period, then Siemens will not bill the travel time to
Stereotaxis. The response time for Siemens to provide to any customer the
services described in Sections 14(b)(i) through 14(b)(iii) inclusive shall not
exceed 4 hours during the customer's principal coverage period; provided,
however, that the time during which Siemens is waiting for Stereotaxis' approval
to dispatch a CSE to the customer site shall not count towards the 4 hours'
response time requirement.

     15.  STEREOTAXIS TECHNICAL SUPPORT.

     (a) Stereotaxis will provide 24x7 hours technical support to Siemens' CSEs.
The initial support plan is as follows:

          o    Stereotaxis will create a toll-free, dedicated service support
               telephone number.

          o    This number will ring at key personnel's desks in St. Louis
               during regular work hours. If the line is not answered within 4
               rings or it is after regular business hours, the call will
               forward to an answering service.

          o    The answering service will page the on-call service support
               engineer.

          o    Response time for technical support is within 2 hours of call
               receipt.

          o    Technical support will log all inbound calls including all
               pertinent information such as date, time, customer, problem
               description, problem resolution, etc.

     (b) After Stereotaxis has completed a sufficient number of sales of
Stereotaxis Products, Stereotaxis will investigate the following alternatives
based upon the service needs/frequency of calls/installed base requirements
gathered during the initial sales phase. The preferred option of Stereotaxis
will be discussed and agreed by Siemens before implementation:

     o    Option 1. Establish a dedicated support staff that are available 24x7
          hours and are Stereotaxis employees.

     o    Option 2. Outsource technical support to a 3rd party company that is
          staffed 24x7 hours. This will require in depth training for the 3rd
          party company. Maintain a level 3 support response on an as required
          pager basis.

                                        5
<PAGE>

     o    Option 3. Should after hours support needs be low as the mean time
          between failures ("MTBF") is found to be very high, Stereotaxis may
          elect to stay with after hours technical support provided on an as
          required pager basis.

     16. SPARE PARTS LOGISTICS. All spare parts necessary to repair the
Stereotaxis Products shall be provided to Siemens at no charge.

     (a) SPARE PARTS LIST. Stereotaxis will create a recommended spare parts
list. This list will include anticipated replacement parts items along with
expected MTBF.

     (b) SPARE PARTS INVENTORY. Stereotaxis will maintain an inventory of spare
parts in the United States. Spare parts will be defined and assigned Stereotaxis
and Siemens part numbers according to service needs and requirements. Returnable
parts will be marked with "REP". Spare parts inventory levels will be determined
by Stereotaxis. At a minimum Stereotaxis will review inventory levels annually
and make any necessary adjustments based upon usage. If Siemens elects, it can
stock above the inventory level established by Stereotaxis by purchasing
additional parts from Stereotaxis. Stereotaxis will reimburse Siemens for parts
used from this additional inventory level.

     (c) PARTS ORDERING AND ORDER FULFILLMENT. For the Siemens CSE, the process
for order processing and fulfillment will be the same as for Siemens parts:

          o    Siemens CSE identifies the need for replacement part(s) and
               places an order as with Siemens spare parts.

          o    The order is processed by Siemens and shipped by the order
               processing and fulfillment center.

          o    Certain pre-selected parts, based upon cost or complexity,
               require pre-approval by Stereotaxis' service personnel to ensure
               complete and accurate troubleshooting has been conducted.

          o    Siemens ships returnable parts (REP) to Stereotaxis.

          o    Stereotaxis repairs returned parts as appropriate and returns
               them to service stock.

     17. TECHNICAL TRAINING.

     (a) In order for Siemens' service personnel to be adequately prepared to
service the Stereotaxis Products, Stereotaxis will provide technical training
classes (including on-site training) for a commercially reasonable number of
Siemens service personnel and will, based on reasonable requests by Siemens,
make such classes available at various locations, including (i) St. Louis (at
the Stereotaxis facility) for Niobe stand alone training, (ii) Forchheim,
Germany (at the Siemens facility) for the first year or until the Niobe system
is de-installed, and (iii) at customer facilities.

     (b) The training materials to be provided by Stereotaxis shall contain, at
a minimum, the following: (i) theory of operation, (ii) installation &
calibration, (iii) interface with Siemens Products, (iv) user interface, (v)
periodic maintenance, (vi) troubleshooting, (vii) hands-on lab time, and (viii)
magnetic precautions and personal safety.

     (c) Course length will vary but will generally consist of 3-5 days of
instruction. Two Siemens CSEs will be trained for each Niobe installation (a
primary and a secondary CSE). Should additional training be required later
(e.g., due to any personnel changes), it will be provided with the next training
class/on site training under the same conditions. All costs for delivering
training shall be borne by Stereotaxis. Travel expenses for Siemens CSEs,
including airfare, meals and lodging, while attending training shall be borne by
Siemens.

     18. FIELD MODIFICATION INSTRUCTIONS AND TRACEABILITY.

     (a) Stereotaxis will maintain files that track software and hardware
revisions for all customers. All installed updates will have return paperwork
that will trigger a revision to this database upon receipt.

                                       6
<PAGE>

     (b) For all Field Modification Instructions (FMIs), Stereotaxis will
contract Siemens to install the updates. Safety FMIs will be installed on an
emergency basis; routine FMIs will be installed at the next routine service
calls. Siemens will be reimbursed for these services on a time basis in
accordance with the rates set forth on Exhibit A attached hereto.

     (c) Distribution of the FMIs and routing of return paperwork for
traceability shall be agreed to by the parties, with the goal of using Siemens
normal distribution channels. Stereotaxis will write the instructions and
Siemens will distribute the FMIs to the responsible person(s) within Siemens. If
parts are needed they will be handled like spare parts with a Siemens Part
number and distributed by the order processing and fulfillment center.

     19. SERVICE DOCUMENTATION. Stereotaxis will develop the following service
documents for the Stereotaxis Products. Stereotaxis will provide a hard copy of
such documents (in English) to each customer and such documents will be provided
in Adobe Acrobat Portable Document Format (PDF) for Siemens" internal use and
distribution.

       Site Planning Guide
       Pre-Installation Manual
       Installation Manual
       Service Manual
       Periodic Maintenance
       Parts & Special Tools Manual
       User Manual
       System Maintenance Requirements, Hazardous Waste Disposal instructions

     20. SERVICE TOOLS. Standard service tools will be used by Siemens during
installation of the Stereotaxis Products prior to the time of magnet mounting.
Specialized tools required for installation of the magnet and for servicing of
the same will be provided by Stereotaxis and will remain on the customer site
after installation is completed. The kit will include the test leads for limit
switch adjustment and a small kit of fuses, drift pins, etc. Stereotaxis will
provide Siemens with a list of part numbers of the specialized tools and the
toll kit in order to expedite any ordering of additional items. Subsequent
service work performed by both Siemens and Stereotaxis can be performed using
standard tools so long as adequate safety precautions are taken. Service
training shall include instruction on such safety precautions.

     21. ACCESS. Stereotaxis will provide Siemens with access to the equipment
being serviced, subject to Stereotaxis' customers' reasonable security
requirements. Stereotaxis' personnel will be available to respond to Siemens'
technicians when Siemens is performing Services.

     22. INSURANCE. At all times throughout the term of this Agreement, Siemens
shall maintain in full force and effect the following insurance coverage, and
shall provide Stereotaxis with a certificate of insurance evidencing such
coverage upon request of Stereotaxis:

     (a) Workman's compensation insurance in accordance with the jurisdiction in
which the work is to be performed.

     (b) General liability Insurance with limits of at least [***] per
occurrence and an annual aggregate of [***].

     23. INDEPENDENT CONTRACTORS. Based solely on this Agreement, and without
regard to relationships based on other agreements to which Siemens and
Stereotaxis may be parties, Siemens and Stereotaxis are independent contractors,
neither is the agent or representative of the other; and neither is authorized
to enter into any agreements to bind the other. The relationship between Siemens
and Stereotaxis based on this Agreement shall remain that of independent
contractors and nothing herein shall create or imply any relationship or
agreement of joint venture, partnership, franchise, or hire. Siemens' personnel
that are assigned to perform any Services hereunder shall be and remain at all
times during such assignment employees of Siemens. Siemens and its employees and
personnel shall be solely responsible for any and all city, state and federal
income taxes, social security

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]

                                       7
<PAGE>

withholding taxes and any other tax obligation to which the employees and
personnel of Siemens may be subject. NEITHER PARTY HAS AUTHORITY TO ASSUME OR
CREATE ANY OBLIGATIONS ON THE OTHER'S BEHALF, EXPRESS OR IMPLIED, WITH RESPECT
TO THE PRODUCTS OR OTHERWISE. Without limiting the generality of the foregoing,
neither party shall make any representation, guarantee or warranty on the other
party's behalf. Neither party shall use the other party's company name, logo,
artwork designs or abbreviations thereof in any way which may result in
confusion as to Stereotaxis and Siemens being separate entities.

         24.      CONFIDENTIAL INFORMATION.  During the term of this Agreement,
and in fulfilling each party's obligations under this Agreement, the parties
and their respective employees and agents will be exposed to and learn
confidential information belonging to the other party. All confidential
information shall be and remain the sole property of the disclosing party and
may only be used or disclosed by the receiving party and its employees and
agents for the sole purpose of fulfilling its obligations under this Agreement
and for no other purpose. The parties shall use all reasonable precautions to
assure that the confidential information of the disclosing party is protected
from unauthorized persons and from unauthorized use or disclosure. The
restrictions on disclosure of confidential information shall not apply to
information (i) which is or becomes public knowledge through no fault of the
receiving party and its employees and agents, or any third party not under an
obligation of non-disclosure to the disclosing party, (ii) which is made
available to the receiving party or its employees or agents by an independent
third party with no obligation of non-disclosure to the disclosing party, (iii)
which is already in the possession of the receiving party or its employees or
agents at the time of receipt from the disclosing party (and such prior
possession can be properly demonstrated by documentary evidence), or (iv) which
is required by law to be disclosed. Confidential information shall not be
deemed to be public knowledge merely because any part of said information is
embodied in general disclosures or because individual features, components or
combinations thereof are now or become known to the public. The receiving
party's obligations with respect to confidential information shall continue for
a period of five (5) years from the expiration or termination of this
Agreement. For purposes of this Agreement, "confidential information" means any
information belonging to the disclosing party which it considers to be valuable
and proprietary including but not limited to, know-how, technical data,
processes, diagnostic software, techniques, developments, inventions, research
products, and plans for future developments, and proprietary matter of a
business or technical nature, including but not limited to information about
cost, profits, markets, products sales, and names and lists of customers.
confidential information includes all written materials (including
correspondence, memoranda, manuals, notes and notebooks) and all computer
software, models, mechanisms, devices, programs, drawings, or plans which shall
be disclosed or made available embodying confidential information.

         25.      SOFTWARE LICENSE.

         (a)      To perform its obligations under this Agreement, Siemens may
need to use certain Stereotaxis software ("Software"). This Software is and
shall remain included in the definition of Confidential Information.
Stereotaxis hereby grants to Siemens a royalty-free, non-assignable,
non-exclusive license to use the Software solely to service equipment as
required to fulfill Siemens' obligations under this Agreement and for no other
purpose. Upon termination of this Agreement, the Software (and all full or
partial copies thereof) will be returned to Stereotaxis or Siemens will certify
as to the destruction thereof.

         (b)      Except as provided in Section 25(a) above, Siemens has no
right, title or interest in the Software, including but not limited to, no
right to (a) make or have made any copy or copies of the Software except as
otherwise required to perform its obligations under this Agreement, (b) make or
have made any products incorporating all or any part of the Software, (c)
modify, adapt, disassemble or create any derivative work or works based on the
Software, unless in any case consented to by Stereotaxis.

         (c)      Siemens shall use its best efforts to ensure that its
employees comply with the restrictions herein. Siemens shall make its employees
aware of the limited scope of this license. Siemens will, at its sole cost and
expense, upon the written request of Stereotaxis, take any action reasonably
requested to prevent any unauthorized use of the Software arising out of or
caused by Stereotaxis' license of the Software to Siemens.

                                       8

<PAGE>

26.  NOTICES. All notices from one party to the other under this Agreement shall
     be in writing and either personally delivered or sent by overnight delivery
     service or certified mail (E-mail or other electronic media are not
     acceptable), postage prepaid and return receipt requested to:

                     Stereotaxis:  Stereotaxis, Inc.
                                   4041 Forest Park Ave.
                                   St. Louis, MO 63108
                                   Attn: CEO and CFO

                     Siemens:      Siemens Medical Solutions USA, Inc.
                                   110 MacAlyson Court
                                   Cary, NC 27511-6495
                                   Attn: Richard Kubsch

                     With copy to: Siemens Corporation
                                   Legal Department
                                   Associate General Counsel
                                   51 Valley Stream Parkway
                                   Malvern, PA 19355

or to such other person or places as either party may designate from time to
time by notice hereunder. Such notices shall be deemed effective upon receipt if
sent by personal delivery or by overnight delivery service or three (3) days
after deposit in the mails in accordance herewith.

     27. GOVERNING LAW; JURISDICTION. This Agreement shall be governed by and
construed in accordance with the laws of the State of New Jersey, without giving
effect to choice of laws provisions thereunder.

     28. SEVERABILITY. If any one or more of the provisions, or portions of
provisions, of this Agreement shall be deemed by any court or quasi-judicial
authority to be invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions, or portions of
provisions contained herein, shall not in any way be affected or impaired
thereby, so long as the Agreement still expresses the intent of the parties. If
the intent of the parties cannot be preserved, this Agreement shall either be
renegotiated or rendered null and void.

     29. LANGUAGE CONSTRUCTION. The language of this Agreement shall be
construed in all cases, according to its fair meaning, and not for or against
any party hereto. The parties acknowledge that each party and its counsel have
reviewed this Agreement and that the normal rule of construction to the effect
that any ambiguities are to be resolved against the drafting party shall not be
employed in the interpretation of this Agreement.

     30. DISPUTE RESOLUTION. Any disputes or differences arising from or
relating to this Agreement or the breach, termination, or validity thereof,
whether at common law or under statute shall be settled by an amicable effort of
the parties. An attempt to arrive at a settlement shall be deemed to have failed
as soon as one party so notifies the other party in writing. If an attempt at
settlement has failed, such disputes and differences shall be exclusively and
finally settled by arbitration brought before the American Arbitration
Association in New York, New York, according to its Commercial Arbitration
Rules, by three (3) arbitrators appointed in accordance with such Rules. Unless
prohibited or restricted by law, each party agrees to provide to the arbitrators
and to the other party such documents, other evidence or witness testimony as
may reasonably be requested by the other party and as are relevant to the issues
being arbitrated. Such request shall be subject to a strict confidentiality
agreement and shall not affect time limits provided for in such Rules and/or in
this Agreement. The award, determinations and decisions of the arbitrators shall
be substantiated in writing. The arbitration tribunal shall decide on the matter
of costs of the arbitration and which of the parties shall bear the costs or in
what proportions the costs shall be borne by the parties. The award of the
arbitrators shall be final and binding, and no appeal shall lie therefrom.
Judgment on the award or any order final or interim ordered

                                       9

<PAGE>

by the arbitrators may be entered, registered or filed for enforcement purposes
in any court having jurisdiction thereof.

     31. GOVERNMENT ACCESS CLAUSE. Until the expiration of four (4) years after
the furnishing of any services under this Agreement, the parties shall make
available upon written request of the Secretary of Health and Human Services,
the Comptroller General, or any of their duly authorized representatives, this
Agreement and the books, documents and records of the each of the parties that
are necessary to certify the nature and extent of costs incurred under this
Agreement or any agreements that Stereotaxis enters into with customers for the
sale, installation and servicing of the Stereotaxis Products. This clause shall
apply if, and solely to the extent that, Section 1861(V)(1)(I) of the Social
Security Act applies to this Agreement or any agreements that Stereotaxis
enters into with customers for the sale, installation and servicing of the
Stereotaxis Products.

     32. DEBARMENT CERTIFICATION. The parties each represent that (i) neither it
nor any of its employees or agents has been debarred, excluded or suspended
from, or otherwise determined to be ineligible to participate in, Medicare,
Medicaid or any other federal or state health care programs, nor is it or any of
its employees or agents the subject of any inquiry or investigation regarding
participation in such programs which could reasonably lead to suspension,
debarment or exclusion from, or ineligibility to participate in, such programs,
(ii) neither it nor any of its employees or agents has ever been convicted of a
criminal offense related to the provision of health care items or services, and
(iii) it shall not knowingly employ or contract with, with or without
compensation, any individual or entity listed by a federal agency as debarred.
The parties hereby agree to promptly notify the other party of any threatened,
proposed, or actual exclusion from Medicare, Medicaid or any federal or state
health care programs. In the event that a party or any of its employees or
agents is debarred, excluded or suspended from, or otherwise determined to be
ineligible to participate in, Medicare, Medicaid or any federal or state health
care programs during the term of this Agreement, or if at any time after the
Effective Date, it is determined that a party is in breach of this Section 32,
this Agreement shall, at the option of the other party as of the effective date
of such debarment, exclusion, suspension or breach, terminate.

     33. HIPAA. Without limiting the obligations of either party as otherwise
set forth in this Agreement or imposed by applicable law, the parties agree and
acknowledge that they shall comply with all applicable requirements of the
Health Insurance Portability and Accountability Act ("HIPAA"). Without limiting
the generality of the foregoing, the parties represent and warrant that they
will appropriately safeguard protected health information ("PHI") of their
respective customers that is made available to or obtained by the parties
pursuant to this Agreement or otherwise in the course of performing services
hereunder, and that they shall each indemnify and hold the other party harmless
from any and all claims, liabilities, damages, suits, causes of action,
judgments, penalties, fines, costs and expenses arising from or related to that
party's breach of the foregoing. The parties agree that this Agreement shall be
amended from time to time if, and to the extent required by, the provisions of
HIPAA and regulations promulgated thereunder, in order to assure that this
Agreement is compliant therewith.

     Specifically, each of the parties agrees that it shall:

     (a) not use or further disclose PHI other than as permitted or required by
this Agreement or as required by law;

     (b) use appropriate safeguards to prevent use or disclosure of PHI other
than as provided for by this Agreement;

     (c) report to the other party and customer any use or disclosure of PHI of
such customer not provided for by this Agreement of which a party becomes aware;

     (d) ensure that any approved subcontractors who may have access to PHI
agree to the same restrictions and conditions that apply to the parties with
respect to PHI;

                                       10
<PAGE>

     (e) make PHI available to the customer in accordance with applicable law;

     (f) make its internal practices, books, and records relating to the use and
disclosure of PHI received from Siemens or customer available to the Secretary
of the United States Health & Human Services for purposes of determining the
customer's compliance with applicable law; (in addition, a party shall
immediately notify the other party and the customer upon receipt by that party
of any such request, and shall provide the other party with copies of any such
materials);

     (g) make available the information required to provide an accounting of
disclosures of PHI pursuant to applicable law, and

     (h) on termination of this Agreement, return or destroy all PHI that a
party still maintains in any form and retain no copies of PHI.

     34. FURTHER ASSURANCES. Each party agrees to do such further acts, execute
such further documents, secure such written assignments and acknowledgments
necessary to carry out the terms and conditions hereof.

     35. ADDITIONAL DOCUMENTS. Each of the parties hereto agrees to execute any
document or documents that may be reasonably requested from time to time by the
other party to implement or complete such party's obligation pursuant to this
Agreement

     36. WAIVER. No term or provision of this Agreement, or of the Exhibits
attached hereto, shall be deemed to be waived, or a breach excused, unless such
waiver or consent shall be in writing and signed by the party claimed to have
waived or consented. Any waiver of a breach, whether express or implied, shall
not constitute a consent to or waiver of any different or subsequent breach.

     37. ADVERSE ACTS. Each party shall not at any time engage in any acts
(including entry into any agreements or arrangements with third parties) to
oppose, dilute, reduce, defeat, or adversely affect the rights of the other
party under this Agreement.

     38. HEADINGS; NUMBER. The titles or headings used herein are inserted
merely for convenience and shall be given no legal effect. Whenever the context
so requires, the masculine shall include the feminine and neuter, and the
singular shall include the plural, and conversely.

     39. ENTIRE AGREEMENT. This Agreement, together with the attached Exhibits,
each of which is incorporated fully and is made part of this Agreement by this
reference, sets forth the entire and only agreement between Siemens and
Stereotaxis concerning the subject matter hereof. No provisions of this
Agreement can be modified except by a written amendment signed by both parties.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first written above.

SIEMENS MEDICAL SOLUTIONS USA, INC.     STEREOTAXIS, INC.

By:     /s/ Richard Kubsch              By:         /s/ Nicola Young
   --------------------------------         ------------------------------------

Title:       Product Manager            Title:            CFO
       ----------------------------            ---------------------------------

Date:          11-24-02                 Date:           11/18/02
      -----------------------------           ----------------------------------

                                       11
<PAGE>

                        EXHIBIT A -- PRICING FOR SERVICES

CREATION OF SITE PLANS (Reference: Section 10(a) of the Agreement): Stereotaxis
will reimburse Siemens for Site Planning services for all booked orders at the
rate of [***] per hour; Siemens estimates that for most projects the cost of
these services will be [***] (6 hours of work). Preliminary site plans for lost
orders can be billed to Stereotaxis should the quantity of these plans become
excessive.

PROJECT MANAGEMENT (Reference: Section 11(a) of the Agreement): . Stereotaxis
will reimburse Siemens for Project Management services at the rate of [***] per
hour; Siemens estimates that for most projects the cost of these services will
be [***] (34 hours).

WARRANTY/SUPPORT SERVICES (References: Sections 14(e) and 18(b) of the
Agreement):
Stereotaxis will reimburse Siemens for travel and services performed by Siemens
and referred to in Sections 14(e) and 18(b) of the Agreement at Siemens'
current applicable commercially reasonable hourly rates, which rates, at the
date of the Agreement, are those specified in Schedule 1 for Angio/Cardiac under
the subheadings "All Travel", "Regular", "Overtime", and "Double time", subject
to the following discount schedule:

0 -- 100 hours in 1 year or less: a [***] discount will be granted off the
applicable rates.

101 -- 200 hours in 1 year or less: a [***] discount will be granted off the
applicable rates.

201 hours and more in 1 year or less: a [***] discount will be granted off the
applicable rates.

The hours will be monitored quarterly and the discounts adjusted, if applicable.

SPARE PART LOGISTICS (Reference: Section 16 of the Agreement):
Costs for the handling fees incurred by Siemens for returns processing and to be
paid by Stereotaxis will be determined under separate agreement or amendment to
the Agreement.

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]

                                       12

<PAGE>

                                   SCHEDULE 1

HOURLY SERVICE RATES

The following hourly service rates will be in effect as of June 15, 2002. These
rates are subject to change in accordance with the then applicable commercially
reasonable rates of Siemens.

                                     [***]

GENERAL TERMS

Regular time hours will be in effect from 8:00 AM - 5:00 PM, Monday - Friday,
excluding Siemens holidays.

Overtime hours will be in effect from 5:00 PM -- 8:00 AM, Monday - Friday, and
all day Saturday until 5:00 PM.

Double time hours will be in effect from 5:00 PM Saturday - 8:00 AM Monday, and
on the following Siemens holidays: New Years Day, Memorial Day (observed),
Independence Day, Labor Day, Thanksgiving Day, Christmas Day. If one of the
foregoing holidays falls on a Saturday, then the holiday will be observed on the
previous Friday, and if the holiday falls on a Sunday, the holiday will be
observed on the following Monday.

A minimum charge of 4 hours plus travel time applies for labor requested
outside of regular working or contract coverage hours.

TIME AND MATERIAL CUSTOMERS

Customers will be charged at the applicable billing rate for the hours worked
at either the regular, overtime or double-time rate plus travel.

[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]

                                       13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]